Navigation Links
Modell Chair in Pediatric Immunology established
Date:2/16/2011

The Children's Hospital of Philadelphia has announced the establishment of the Jeffrey Modell Endowed Chair in Pediatric Immunology Research.

A ceremony on Feb. 15 at the Hospital's Ruth and Tristram Colket, Jr. Translational Research Building recognized the first holder of the chair, pediatric immunologist Jordan S. Orange, M.D., Ph.D. The chair's $2 million endowment will allow Dr. Orange to break new ground in his ongoing research. Dr. Orange is internationally prominent for studying and treating primary immunodeficiency disorders in children.

"We appreciate the generosity of Fred and Vicki Modell for their continuing support of Dr. Orange's important work," said Steven M. Altschuler, M.D., chief executive officer of The Children's Hospital of Philadelphia. "This gift will advance the efforts by Dr. Orange and the Jeffrey Modell Foundation to translate scientific knowledge into real improvements in children's lives."

Dr. Altschuler presented the endowed chair to Dr. Orange. Fred and Vicki Modell spoke at the ceremony, as did Alan R. Cohen, M.D., physician-in-chief of Children's Hospital.

Dr. Orange is already the director of the Jeffrey Modell Diagnostic Center at Children's Hospital, a premier program among dozens of centers worldwide that have been established by the Jeffrey Modell Foundation to provide expert diagnosis and treatment to patients with primary immunodeficiency diseases. Co-founded by Fred and Vicki Modell in 1986, the Foundation honors the memory of their son Jeffrey, who died at age 15 from complications of primary immunodeficiency.

Primary immunodeficiencies include over 150 genetic disorders in which the immune system's ability to produce specific antibodies to fight off infection is greatly impaired or absent. Early diagnosis and treatment are essential to preventing recurrent infections from doing permanent damage.

Dr. Orange's research focuses on the biology of natural killer cells and the innate immune system, with a clinical focus on primary immunodeficiency disease. He has received funding from the National Institute of Allergy and Infectious Diseases and the United States Immunodeficiency Network to support his laboratory work, and has authored over 100 scientific publications. In 2009 the American Philosophical Society awarded him the Judson Daland Prize for Clinical Investigation, which honors outstanding achievements in patient-oriented research.

Over the past decade, Dr. Orange has redefined the field of human natural killer cell deficiencies in various genetic disorders. He recently collaborated with European researchers who achieved marked clinical improvements in using gene therapy to treat young children with Wiskott-Aldrich syndrome, a rare but often severe immunodeficiency disorder. At Children's Hospital, he is currently conducting clinical trials testing the use of immunotherapy to boost immune function in children with Wiskott-Aldrich syndrome.

In addition to his duties at The Children's Hospital of Philadelphia, Dr. Orange is on the Pediatrics faculty of the University of Pennsylvania School of Medicine and is an elected member of the American Society for Clinical Investigation.


'/>"/>

Contact: Rachel Salis-Silverman
Salis@email.chop.edu
267-426-6063
Children's Hospital of Philadelphia
Source:Eurekalert

Related biology news :

1. Clinical trial shows quadriplegics can operate powered wheelchair with tongue drive system
2. McGill garners 19 Canada Research Chairs and more than $17 million in funding
3. Study shows that color plays musical chairs in the brain
4. New biomedical engineering chair earns high honors
5. Salk Institute creates Renato Dulbecco Chair in Genomics and Roger Guillemin Chair in Neuroscience
6. Armchair nanoribbons made into spintronic device
7. Innovations in Pediatric Medicine CME conference brings together national pediatrics experts
8. Innovations in Pediatric Medicine International Conference brings together pediatrics experts
9. Gene mutation increases drug toxicity, rejection risk in pediatric kidney transplants
10. Childrens Hospital Oakland is first pediatric hospital to use laboratory-on-a-card technology
11. Childrens National experts present at Pediatric Academic Societies Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/30/2016)... 2016  higi SH llc (higi) announced today ... national brands, industry thought-leaders and celebrity influencers looking ... for taking steps to live healthier, more active ... higi has built the largest self-screening health station ... people who have conducted over 185 million biometric ...
(Date:11/24/2016)... , Nov. 23, 2016 Cercacor today introduced ... and their trainers non-invasively measure hemoglobin, Oxygen ... Rate, and Respiration Rate in approximately 30 seconds. Smaller ... easy and immediate access to key data about their ... a training regimen. Hemoglobin carries oxygen ...
(Date:11/17/2016)... Global Market Watch: Primarily supported by ownership types; ... Academics) market is to witness a value of US$37.1 billion ... Compounded Annual Growth Rate (CAGR) of 10.75% is foreseen from ... 2014-2020. North America is not way ... Europe at 9.56% respectively. Report Focus: ...
Breaking Biology News(10 mins):
(Date:12/9/2016)... 2016 China Cord Blood Corporation (NYSE: ... leading provider of cord blood collection, laboratory testing, hematopoietic ... the results of its 2016 Annual General Meeting, which was ... China . At the Annual ... of KPMG Huazhen LLP as the independent auditors of the ...
(Date:12/8/2016)... ... December 08, 2016 , ... Lajollacooks4u, San Diego’s premier team building ... team building events, new program offerings and company expansion. , This is ... to include groups of over 30 people. Ever since, Lajollacooks4u has seen significant demand ...
(Date:12/8/2016)... , Dec. 8, 2016  Renova™ Therapeutics, ... congestive heart failure and type 2 diabetes, announced ... a novel adeno-associated virus (AAV) vector developed in ... M.D., Ph.D., at Stanford University. The company plans ... paracrine gene therapy product pipeline. ...
(Date:12/8/2016)... OXFORD, England , December 8, 2016 ... Company, has expanded its customisable SureSeq™ NGS panel range with ... - allowing fast and cost-effective study of variants in familial ... copy number variation (CNV) detection on a single small panel ... and hotspot content. This includes all exons for LDLR ...
Breaking Biology Technology: